GILEAD SCIENCES INC (GILD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for GILD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GILD | Former Chair of Board of Directors, Biotechnology Innovation Organization | 67 | ["Significant leadership experience in the biopharma industry, including serving as a chief executive officer of a global healthcare company", "Physician with a strong scientific background, known for championing access to care"] | ["Audit Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| JAZZ | Director, Gilead Sciences, Inc., Royalty Pharma plc, and Structure Therapeutics Inc.; Member | 67 | ["More than 30 years of biopharmaceutical leadership","Expertise in drug development","Commercialization","Public policy"] | ["Audit Committee","Compensation Committee","Nominating Committee"] | 2026 |
| BIO | Executive Vice President, Research and Development | 53 | ["technical, financial and business expertise", "years as a researcher", "executive and director of various public companies"] | [] | 2012 |
Biography sourced from the proxy statement filing.
Ted W. Love, M.D. Independent Age: 67 Director since: 2024 Board Committees Audit Other Public Company Board Service: Jazz Pharmaceuticals plc Royalty Pharma plc Structure Therapeutics Inc. CAREER HIGHLIGHTS Biotechnology Innovation Organization , a trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other countries Chair of Board of Directors (2023-2025) Global Blood Therapeutics, Inc. , a biopharmaceutical company President and Chief Executive Officer from 2014 to 2022, leading the company from a pre-clinical startup through its growth to a global commercial company with a pipeline of innovative therapies focused on sickle cell disease Other Pharmaceutical and Biotechnology Experience Onyx Pharmaceuticals, Inc. - Executive Vice President, Research and Development and Technical Operations Nuvelo, Inc. - President, Chief Executive Officer and Chairman Theravance Biopharma, Inc. - Senior Vice President, Development Genentech, Inc. - Senior management positions in clinical science and product development, including Chair of Genentech s Product Development Committee Massachusetts General Hospital Physician in Department of Cardiology OTHER PROFESSIONAL HIGHLIGHTS AND ITEMS OF NOTE Recipient of William E. Proudford Sickle Cell Fund Distinguished Service Award (2023) Recipient of Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists (2023) Former director of Seagen Inc. (2020-2023) and Global Blood Therapeutics (2013-2022) RELEVANT SKILLS AND EXPERIENCE Significant leadership experience in the biopharma industry , including serving as a chief executive officer of a global healthcare company Physician with a strong scientific background , known for championing access to care